bf/NASDAQ:SABS_icon.jpeg

NASDAQ:SABS

SAB Biotherapeutics, Inc.

  • Stock

USD

Last Close

2.77

21/06 20:00

Market Cap

55.12M

Beta: 1.26

Volume Today

17.82K

Avg: 1.39M

PE Ratio

−10.36

PFCF: 7.38

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza...Show More

Earnings per Share (Estimate*)

-1-0.50.52021-05-212021-12-312022-08-102023-05-162024-02-192024-05-14

Revenue (Estimate*)

10M20M30M40M50M60M2021-05-212021-12-312022-08-102023-05-162024-02-192024-05-14

*Estimate based on analyst consensus